Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Connect with investors, share insights, and grow together
Stay up to date on latest investing trends and other announcements
Explore our range of financial tools to streamline your investment planning
A structured, comprehensive way to understand global investing
Read about our journey and get to know the leadership team at Vested
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering (lead drug) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval. more
| Time Frame | BBC | S&P500 |
|---|---|---|
| 1-Week Return | -1.54% | 0.77% |
| 1-Month Return | 9.35% | 3% |
| 3-Month Return | 21.52% | 1.43% |
| 6-Month Return | 26.2% | 12.03% |
| 1-Year Return | 129.72% | 20.13% |
| 3-Year Return | 148.2% | 70.9% |
| 5-Year Return | 11.63% | 70.4% |
| 10-Year Return | 166.2% | 254.47% |
| Time Frame | BBC | S&P500 |
|---|---|---|
| 1-Week Return | -55.48% | 49.18% |
| 1-Month Return | 196.68% | 43.28% |
| 3-Month Return | 120.44% | 5.93% |
| 6-Month Return | 60.30% | 25.90% |
| 1-Year Return | 129.72% | 20.13% |
| 3-Year Return | 35.39% | 19.56% |
| 5-Year Return | 2.22% | 11.25% |
| 10-Year Return | 10.29% | 13.49% |
| Stock name | Ticker | Weight |
|---|---|---|
Amylyx Pharmaceuticals Inc | AMLX | 1.48% |
First Tracks Biotherapeutics Inc | TRAX | 1.47% |
AbCellera Biologics Inc | ABCL | 1.34% |
Xencor Inc | XNCR | 1.31% |
Monopar Therapeutics Inc | MNPR | 1.16% |
AtaiBeckley Inc | ATAI | 1.15% |
MBX Biosciences Inc | MBX | 1.1% |
uniQure NV | QURE | 1.1% |
Replimune Group Inc | REPL | 1.08% |
SELLAS Life Sciences Group Inc | SLS | 1.05% |
LB Pharmaceuticals Inc | LBRX | 1.04% |
4D Molecular Therapeutics Inc | FDMT | 1.03% |
Definium Therapeutics Inc | DFTX | 1.03% |
Immix Biopharma Inc | IMMX | 1.02% |
Alto Neuroscience Inc | ANRO | 1.02% |
ORIC Pharmaceuticals Inc | ORIC | 0.99% |
Cullinan Therapeutics Inc | CGEM | 0.98% |
Zenas Biopharma Inc | ZBIO | 0.98% |
Vor BioPharma Inc | VOR | 0.98% |
Nurix Therapeutics Inc | NRIX | 0.96% |
Candel Therapeutics Inc | CADL | 0.95% |
Immunome Inc | IMNM | 0.93% |
Assembly Biosciences Inc | ASMB | 0.92% |
Achieve Life Sciences Inc | ACHV | 0.91% |
Sana Biotechnology Inc | SANA | 0.91% |
REGENXBIO Inc | RGNX | 0.9% |
MeiraGTx Holdings plc | MGTX | 0.89% |
SpyGlass Pharma Inc | SGP | 0.89% |
Viridian Therapeutics Inc | VRDN | 0.88% |
Rocket Pharmaceuticals Inc | RCKT | 0.87% |
Damora Therapeutics Inc | DMRA | 0.87% |
Ideaya Biosciences Inc | IDYA | 0.86% |
Palvella Therapeutics Inc | PVLA | 0.86% |
Dyne Therapeutics Inc | DYN | 0.86% |
Design Therapeutics Inc | DSGN | 0.85% |
Kymera Therapeutics Inc | KYMR | 0.85% |
Solid Biosciences Inc | SLDB | 0.85% |
Biohaven Ltd | BHVN | 0.85% |
Jade Biosciences Inc | JBIO | 0.84% |
Revolution Medicines Inc | RVMD | 0.84% |
Adlai Nortye Group Ltd | ANL | 0.83% |
Inhibrx Biosciences Inc | INBX | 0.83% |
Janux Therapeutics Inc | JANX | 0.82% |
Avalo Therapeutics Inc | AVTX | 0.82% |
GH Research PLC | GHRS | 0.82% |
Scholar Rock Holding Corp | SRRK | 0.81% |
Oruka Therapeutics Inc | ORKA | 0.81% |
Prime Medicine Inc | PRME | 0.81% |
Praxis Precision Medicines Inc | PRAX | 0.8% |
Dianthus Therapeutics Inc | DNTH | 0.8% |
Erasca Inc | ERAS | 0.8% |
Climb Bio Inc | CLYM | 0.79% |
Rapport Therapeutics Inc | RAPP | 0.79% |
Relay Therapeutics Inc | RLAY | 0.79% |
Vaxcyte Inc | PCVX | 0.78% |
Vir Biotechnology Inc | VIR | 0.78% |
Neurogene Inc | NGNE | 0.78% |
Enliven Therapeutics Inc | ELVN | 0.78% |
Invivyd Inc | IVVD | 0.78% |
Celldex Therapeutics Inc | CLDX | 0.78% |
CG oncology Inc | CGON | 0.77% |
Generate Biomedicines Inc | GENB | 0.77% |
Edgewise Therapeutics Inc | EWTX | 0.76% |
Arcus Biosciences Inc | RCUS | 0.76% |
Immunovant Inc | IMVT | 0.76% |
Nektar Therapeutics | NKTR | 0.76% |
Arvinas Inc | ARVN | 0.75% |
Lexicon Pharmaceuticals Inc | LXRX | 0.74% |
Altimmune Inc | ALT | 0.74% |
Arbutus Biopharma Corp | ABUS | 0.74% |
Corvus Pharmaceuticals Inc | CRVS | 0.74% |
Compass Therapeutics Inc | CMPX | 0.73% |
Disc Medicine Inc | IRON | 0.73% |
Tectonic Therapeutic Inc | TECX | 0.73% |
Aktis Oncology Inc | AKTS | 0.73% |
Rezolute Inc | RZLT | 0.72% |
Aura Biosciences Inc | AURA | 0.72% |
Xenon Pharmaceuticals Inc | XENE | 0.71% |
Pharvaris NV | PHVS | 0.71% |
Maze Therapeutics Inc | MAZE | 0.71% |
Compass Pathways Plc | CMPS | 0.71% |
Prothena Corp PLC | PRTA | 0.7% |
BridgeBio Oncology Therapeutics Inc | BBOT | 0.7% |
Viking Therapeutics Inc | VKTX | 0.69% |
Spyre Therapeutics Inc | SYRE | 0.69% |
ProKidney Corp | PROK | 0.69% |
Lexeo Therapeutics Inc | LXEO | 0.69% |
Kodiak Sciences Inc | KOD | 0.69% |
Structure Therapeutics Inc | GPCR | 0.68% |
Oculis Holding AG | OCS | 0.68% |
Belite Bio Inc | BLTE | 0.68% |
Upstream Bio Inc | UPB | 0.68% |
Mineralys Therapeutics Inc | MLYS | 0.67% |
Septerna Inc | SEPN | 0.67% |
Bicara Therapeutics Inc | BCAX | 0.67% |
CytomX Therapeutics Inc | CTMX | 0.66% |
Allogene Therapeutics Inc | ALLO | 0.66% |
Intellia Therapeutics Inc | NTLA | 0.66% |
Stoke Therapeutics Inc | STOK | 0.66% |
Recursion Pharmaceuticals Inc | RXRX | 0.66% |
Annexon Inc | ANNX | 0.65% |
Cogent Biosciences Inc | COGT | 0.65% |
Olema Pharmaceuticals Inc | OLMA | 0.65% |
Bicycle Therapeutics PLC | BCYC | 0.64% |
Cabaletta Bio Inc | CABA | 0.64% |
VeraDermics Inc | MANE | 0.63% |
Taysha Gene Therapies Inc | TSHA | 0.63% |
Beam Therapeutics Inc | BEAM | 0.63% |
Immatics NV | IMTX | 0.63% |
AnaptysBio Inc | ANAB | 0.62% |
Savara Inc | SVRA | 0.62% |
Celcuity Inc | CELC | 0.62% |
Vera Therapeutics Inc | VERA | 0.62% |
Crescent Biopharma Inc | CBIO | 0.61% |
ArriVent Biopharma Inc | AVBP | 0.61% |
Summit Therapeutics Inc | SMMT | 0.61% |
Alumis Inc | ALMS | 0.57% |
Tyra Biosciences Inc | TYRA | 0.57% |
Wave Life Sciences Inc | WVE | 0.53% |
Newamsterdam Pharma Co NV | NAMS | 0.53% |
MoonLake Immunotherapeutics | MLTX | 0.5% |
Tango Therapeutics Inc | TNGX | 0.47% |
Monte Rosa Therapeutics Inc | GLUE | 0.46% |
Evommune Inc | EVMN | 0.41% |
Relmada Therapeutics Inc | RLMD | 0.4% |
BioAge Labs Inc | BIOA | 0.33% |
MapLight Therapeutics Inc | MPLT | 0.28% |
Capricor Therapeutics Inc | CAPR | 0.23% |
EyePoint Inc | EYPT | 0.21% |
Cash/Cash equivalents | Cash.Cash.equivalents | 0.1% |
Sionna Therapeutics Inc | SION | 0.1% |
| Sector | Weight |
|---|---|
|
Health care | 100.00% |
Virtus LifeSci Biotech Clinical Trials ETF (BBC) share price today is $53.05.
Yes, Indians can buy shares of Virtus LifeSci Biotech Clinical Trials ETF (BBC) on Vested. To buy BBC from India, you can open a US Brokerage account by signing up on Vested. The account opening process is completely digital and secure, and takes 3-5 minutes to complete.
Yes, you can purchase fractional shares of Virtus LifeSci Biotech Clinical Trials ETF (BBC) on Vested. You can start investing in Virtus LifeSci Biotech Clinical Trials ETF (BBC) with a minimum investment of $1.
The 52-week high price of Virtus LifeSci Biotech Clinical Trials ETF (BBC) is $56.18. The 52-week low price of Virtus LifeSci Biotech Clinical Trials ETF (BBC) is $22.45.
The stock symbol (or ticker) of Virtus LifeSci Biotech Clinical Trials ETF is BBC.
Yes, you can setup SIP in Virtus LifeSci Biotech Clinical Trials ETF shares. Follow the below steps to create the SIP:
Here is the historical performance of BBC on the Vested app.
The expense ratio of Virtus LifeSci Biotech Clinical Trials ETF (BBC) is 0.79%.
Link copied